{"id":13328,"date":"2024-08-23T01:25:10","date_gmt":"2024-08-22T23:25:10","guid":{"rendered":"https:\/\/valintermed.com\/?p=13328"},"modified":"2024-08-23T01:25:10","modified_gmt":"2024-08-22T23:25:10","slug":"defitsit-atsil-koa-degidrogenazy-s-ochen-dlinnoy-tsepyu-vlcad","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/deficient-in-atsil-koa-dehydrogenase-with-very-long-chain\/","title":{"rendered":"Very long chain acyl-CoA dehydrogenase deficiency (VLCAD)"},"content":{"rendered":"
<\/div>\n

Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD) is an inherited disorder that belongs to a group of fatty acid oxidation disorders. It results from a defect in the enzyme acyl-CoA dehydrogenase, which is responsible for the oxidation of long-chain fatty acids, resulting in the accumulation of incomplete metabolites and a decrease in the body's ability to use fatty acids as an energy source. These processes can cause a variety of clinical manifestations, including hypoglycemia, myopathy, cardiomyopathy, and even life-threatening conditions such as acute metabolic crises. Clinical manifestations most often occur with physical stress, infections, or excessive intervals between meals.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n